Preclinical data show ATH-1020 both mitigated depression-like behaviors and normalized sensory processing deficits in schizophrenia
https://finance.yahoo.com/news/athira-pharma-doses-first-subject-110000307.html
Preclinical data show ATH-1020 both mitigated depression-like behaviors and normalized sensory processing deficits in schizophrenia
https://finance.yahoo.com/news/athira-pharma-doses-first-subject-110000307.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.